Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Total Debt
Short-term and long-term borrowings combined.
Pelthos Therapeutics Inc.AMEX: PTHS
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 2014.4% from a year ago
Total debt stood at $52.93M at the end of Q1 FY2026, up 2014.4% from a year earlier and up 52.0% from the prior quarter. Over 3 fiscal years it compounded at +300.9% a year.
Context
- Total debt amounted to 36.4% of total assets at the end of Q1 FY2026, down 238.3 pp from a year earlier.
- Total debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +2014.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 34.83M USD
- Year-over-year change
- +1493.2%
- 3-year CAGR
- +300.9%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.83M | +1493.2% |
| FY2024 | 2024-12-31 | 2.19M | +72.3% |
| FY2023 | 2023-12-31 | 1.27M | +134.8% |
| FY2022 | 2022-12-31 | 540.43K | — |
Total Debt vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 total debt of $52.93M is the highest of the 4 companies compared; the peer median is $1.06M.
- Its year-over-year change of +2014.4% is the highest of 3, against a peer median of +33.1%.
- Total debt amounts to 36.4% of total assets for PTHS, versus a peer median of 9.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $52.93M | +2014.4% | +300.9% | 36.4% | |
| Mar 2026 | $7.43M | +46.2% | +14.4% | 24.1% | |
| Mar 2026 | $1.06M | — | — | 9.7% | |
| Dec 2025 | $641K | +20.0% | -49.1% | 0.0% | |
| Peer median (excluding PTHS) | $1.06M | +33.1% | -17.3% | 9.7% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.